Skip to main content

Relias Media has upgraded our site!

Please bear with us as we work through some issues in order to provide you with a better experience.

Thank you for your patience.

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Almotriptan malate (Axert) a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist, otherwise known as a “triptan,” was approved by the U.S. Food and Drug Administration (FDA) in May 2001.

Drug Criteria & Outcomes: Almotriptan Formulary Evaluation